HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

  • STATUS
    Recruiting
  • End date
    Sep 30, 2022
  • participants needed
    40
  • sponsor
    Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Updated on 28 January 2021

Summary

To evaluate the safety, dosimetry and efficacy of 99mTc/188Re labeled anti-HER2-single domain antibody (Product Code Name: 99mTc-NM-02 and 188Re-NM-02) SPECT/CT imaging of HER2 expression and radionuclide therapy in Breast Cancer. The SPECT/CT results will compare with the existing gold standard " HER2 expression detection" by biopsy tissue immunohistochemistry (IHC) and/or Fluorescence in Situ Hybridization (FISH) method, and 18F-FDG PET/CT imaging. It also to establish a new theranostic method for non-invasive HER2 expression detection and radionuclide therapy in breast cancer using 99mTc/188Re labeled anti-HER2 single domain antibody.

Description

Anti-HER2 single domain antibody will be labeled with 99mTc and 188Re to prepare 99mTc-NM-02 and 188Re-NM-02, respectively. 99mTc-NM-02 is used as a diagnostic agent for SPECT/CT imaging of HER2 expression, and 188Re-NM-02 is used as a therapeutic drug for radionuclide therapy of HER2-postive Breast Cancer.

Details
Condition Breast Cancer, Breast Cancer Diagnosis, breast carcinoma, cancer, breast, Radiotoxicity
Treatment Injection of 99mTc-NM-02, Injection of 188Re-NM-02
Clinical Study IdentifierNCT04674722
SponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult female, age 18 years or older
Prior diagnosis of breast cancer
Willing to participate in this study and given written informed consent
AST, ALT, BUN, Cr not more than double the normal values
Subjects of childbearing potential must be willing to undergo a pregnancy test prior to enrolment
Patients will only be included in the 188Re-NM-02 study if they meet the
following supplementary criterial: HER2 postive, progression or recurrence
after standard treatment, including surgery, chemotherapy, radiotherapy and
targeted therapy

Exclusion Criteria

Pregnancy (subjects with a positive pregnancy test at baseline screening period or who are planning to become pregnant during the study period)
Breastfeeding (subjects in lactation)
No biopsy tissue sample can be provided for HER2 expression detection
Subjects with pacemakers
Hepatitis B virus infection (including carriers) at screening, ie hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody (anti-HCV) positive, or acquired immunodeficiency disease (HIV) infected, or serum syphilis positive person
Abnormal liver function during baseline screening period : AST or ALT> 2 times the upper limit of normal value (ULN), if the marginal increase of a single index is judged as having no clinical significance by the investigator, it can be retested during the screening period. Once, if 2 times ULN after retesting, consider enrolling)
Impaired renal function during screening: serum creatinine or urea nitrogen > 1.5 times ULN
Within 4 months prior to the baseline screening period , myocardial infarction or other cardiac events requiring hospitalization (unstable angina, etc.), cerebrovascular accident, transient ischemic attack, acute congestive Heart failure or severe arrhythmia (ventricular arrhythmia, atrioventricular block above II)
Subjects with pulmonary embolism or deep vein thrombosis
Various infections that the investigators consider unsuitable for study, including but not limited to patients with various infections requiring further treatment, such as urinary tract infections, respiratory infections, and diabetic foot infections
Patients with abnormal thyroid function during baseline screening period (including but not limited to active hyperthyroidism, hypothyroidism or Hashimoto's thyroiditis)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note